The role of angiogenesis in damage and recovery from ischemic stroke

被引：96

作者：

Arenillas J.F. ^{[1
]}

Sobrino T. ^{[1
]}

Castillo J. ^{[1
]}

Dávalos A. ^{[1
]}

机构：

[1] Stroke Unit, Department of Neurosciences, Germans Trias University Hospital, Badalona, Barcelon 08196, Carretera de Canyet s.n.

来源：

Current Treatment Options in Cardiovascular Medicine | 2007年 / 9卷 / 3期

关键词：

Vascular Endothelial Growth Factor; Ischemic Stroke; Cerebral Ischemia; Hepatocyte Growth Factor; Acute Ischemic Stroke;

D O I：

10.1007/s11936-007-0014-5

中图分类号：

学科分类号：

摘要：

Ischemic stroke is burdened with a high morbidity and mortality in our society. However, there are few effective and largely available therapies for this devastating disease. In additon to advancing acute reperfusion therapies, there is a need to develop treatments aimed to promote repair and regeneration of brain tissue damaged by ischemia (neurorecovery). Therapeutic angiogenesis and vasculogenesis represent novel approaches of regenerative medicine that may help in the cure of patients with acute ischemic stroke. Translation of our knowledge about these processes from the bench to bedside is still underway. Although angiogenesis (the sprouting of new blood vessels from pre-existing vascular structures) is likely to contribute to neurorepair, the finality of the angiogenic response in acute ischemic stroke has not been fully elucidated. The first therapeutic approach to angiogenesis after ischemic stroke would be the modulation of the endogenous angiogenic response. In this setting, early instauration of physical activity, statins, and peroxisome proliferator-activated receptor-γ agonists may enhance angiogenesis and neuroregeneration. Gene therapy with vascular growth factors has been successfully tested in patients affected by chronic myocardial and peripheral ischemia. Regarding brain ischemia, experiments in animal models have shown that the effect of these growth factors is critically affected by the dosage, route of delivery, and time of administration in relation to stroke onset. In addition, the optimal angiogenic substance is unknown. Finally, vectors for gene transfer should be further optimized. Therapeutic vasculogenesis consists of the administration of exogenous endothelial progenitor cells in order to enhance brain repair processes. Endothelial progenitor cells may be recruited in response to cerebral ischemia and participate in reparative vasculogenesis after acute ischemic stroke. Further research is needed to clarify their role and therapeutic applicability in human brain ischemia. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：205 / 212

页数：7

共 50 条

[1]

Murray C.J., Lopez A.D., Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study, Lancet, 349, pp. 1498-1504, (1997)

[2]

Hurtado O., Pradillo J.M., Alonso-Escolano D., Et al., Neurorepair versus neuroprotection in stroke, Cerebrovasc Dis, 21, SUPPL. 2, pp. 54-63, (2006)

[3]

Liu X.S., Zhang Z.G., Zhang R.L., Et al., Stroke induces gene profile changes associated with neurogenesis and angiogenesis in adult subventricular zone progenitor cells, J Cereb Blood Flow Metab, (2006)

[4]

Hayashi T., Noshita N., Sugawara T., Chan P.H., Temporal profile of angiogenesis and expression of related genes in the brain after ischemia, J Cereb Blood Flow Metab, 23, pp. 166-180, (2003)

[5]

Krupinski J., Kaluza J., Kumar P., Et al., Role of angiogenesis in patients with cerebral ischemic stroke, Stroke, 25, pp. 1794-1798, (1994)

[6]

Manoonkitiwongsa P.S., Jackson-Friedman C., McMillan P.J., Et al., Angiogenesis after stroke is correlated with increased numbers of macrophages: The clean-up hypothesis, J Cereb Blood Flow Metab, 21, pp. 1223-1231, (2001)

[7]

Arenillas J.F., Alvarez-Sabin J., Montaner J., Et al., Angiogenesis in symptomatic intracranial atherosclerosis: Predominance of the inhibitor endostatin is related to a greater extent and risk of recurrence, Stroke, 36, pp. 92-97, (2005)

[8]

Asahara T., Masuda H., Takahashi T., Et al., Bone marrow origin of endothelial progenitor cells responsible for post-natal vasculogenesis in physiological and pathological neovascularization, Circ Res, 85, pp. 221-228, (1999)

[9]

Hill J.M., Zalos G., Halcox J.P., Et al., Circulating endothelial progenitor cells, vascular function, and cardiovascular risk, N Engl J Med, 348, pp. 593-600, (2003)

[10]

Zhang Z.G., Zhang L., Jiang Q., Chopp M., Bone marrow-derived endothelial progenitor cells participate in cerebral neovascularization after focal cerebral ischemia in the adult mouse, Circ Res, 90, pp. 284-288, (2002)

← 1 2 3 4 5 →